NCT03401294RecruitingPhase 2
Conversion From Unresectable To Resectable Metastatic Colorectal Cancer.
Conversion From Unresectable To Resectable Liver Metastases In Patients With Liver-Only Metastatic Colorectal Cancer Treated With FOLFOXIRI Plus Bevacizumab. The Conversion Trial.
Source: ClinicalTrials.gov · Last updated 9 May 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
Most patients with mCRC are treated with palliative chemotherapy and only a small number of patients with limited metastatic disease achieve long-term remission following metastasectomy. There is a growing need for more effective treatment in patients with liver-only mCRC to improve the rate of curative resection without compromising QOL.The current study is informed by our patient's needs. It aims to evaluate the rate of conversion therapy in patients with unresectable liver-only mCRC using the combination of FOLFOXIRI and bevacizumab and to assess the association between an early FDG-PT/CT response and other clinical and pathological biomarkers and hepatic metastasectomy.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 32 (estimated)
- First submitted
- 2 Jan 2018
- Start date
- 1 May 2025
- Primary completion date
- 31 Dec 2026
- Lead sponsor
- University of Saskatchewan
- Diseases
- Colorectal cancer
- NCT number
- NCT03401294
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 32
- From 1 May 2025 to the primary completion date, 31 Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Severe or uncompensated concomitant medical conditions.
Other illness
- An active second primary cancer with the exception of squamous cell carcinoma of the skin or an in situ cancer.
Other
- Breastfeeding or pregnancy.
Who the study is looking for
- Adult patients, aged between 18 and 70 years with histologically proven adenocarcinoma or poorly differentiated carcinoma of the colon and rectum with unresectable liver-only metastases and no extra-hepatic disease.
- World Health Organization (WHO) performance status of 0-1.
- No previous chemotherapy for advanced disease.
- Adequate functioning of the bone marrow, liver, and kidneys.
Age in the registry: 18 years to 70 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Allan Balir Cancer Center Coordinator of this site? Confirm its status | Regina | Canada | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.